Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Griffiths, R.R., Johnson, M.W., Carducci, M.A., Umbricht, A., Richards, W.A., Richards, B.D., Cosimano, M.P., Klinedinst, M.A. (2016) Journal of Psychopharmacology
Zusammenfassung
In a double-blind, randomized trial, a high dose of psilocybin produced large and sustained decreases in clinician-rated and self-rated measures of depressed mood and anxiety in patients with life-threatening cancer diagnoses. At 6-month follow-up, approximately 80% showed clinically significant decreases in depression and anxiety.
Schlüsselwörter
psilocybincancerdepressionanxietyend-of-liferandomized trial
Clinical Research